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Abstract 
Intestinal microfold (M) cells are epithelial cells primarily present on Peyer’s patches (PPs) in 
the small intestine. The ability of M cells to shuttle antigens into the PP for appropriate 
immune responses makes M cells a target for next-generation oral vaccine delivery. In this 
regard, discovery of M cell specific receptors are of great interest, which could act as 
molecular tags for targeted delivery of cargo to M cells. Here, using a monoclonal antibody 
we generated to the Sialic acid-binding immunoglobulin-like lectin F (Siglec-F), we show that 
Siglec-F is expressed on mouse M cells in the small intestine. Immunohistochemical 
analysis of the PP tissue sections shows that Siglec-F is expressed on the surface of the M 
cell membrane exposed to the intestinal lumen. Anti-Siglec-F antibody injected into the 
mouse small intestine bound to M-cells, demonstrating the potential to target M cells via 
Siglec-F.  
 
Keywords: Siglec, M cell, oral vaccine, Peyer’s patch 
Abbreviations used: M cell, microfold cell; PP, Peyer’s patch; Siglec, sialic acid-binding 
immunoglobulin-like lectin; UEA-I, Ulex europaeus agglutinin-I; 
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1. Introduction 
Intestinal microfold (M) cells are small intestinal epithelial cells localized on the 
Peyer’s patches (PPs) [1]. M cells actively transport luminal antigens from foods, viruses, 
and bacteria into the PPs, leading to induction of the appropriate immune response [2]. 
Because of the role of M cells in antigen transport, targeted delivery of antigens to M cells 
has recognized as an approach to enhance oral vaccine efficacy [3]. Towards this end, 
several well-defined cell surface markers on M cells have been investigated as targets to 
deliver antigens to M cells. Targets investigated to date include α1-2 fucosylated glycans 
expressed on murine M cells that are recognized by the monoclonal antibody NKM16-2-4 [4], 
and glycoprotein 2 (GP2), an M cell specific protein that can be targeted with an anti-GP2 [5, 
6]. Oral administration of antigen conjugated to either the NKM16-2-4 or anti-GP2 antibody, 
greatly elevated serum IgG and intestinal IgA responses, providing a proof of concept for an 
M cell targeted oral vaccine [4, 5].  
 
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of proteins that 
recognize sialic acid residues on glycoproteins and glycolipids [7]. Siglecs were first 
characterized as immune cell receptors with functions including regulation of cellular 
activation, tolerance induction, and pathogen recognition and uptake [7]. Recent studies, 
however, have revealed that several Siglecs are also expressed on non-immune cells, 
suggesting that Siglecs play roles beyond modulating immune cell responses. For example, 
Siglec-4 is well known to be expressed primarily on oligodendrocytes of the central nervous 
system [7], Siglec-6 in the placenta [8], Siglec-12 in the prostate and kidney [9], Siglec-5/14 
on amniotic epithelium [10], and Siglec-5 on human M cells [11]. Due to their restricted 
expression pattern and efficient endocytic properties, Siglecs remain promising targets for 
delivering therapeutics to specific immune and non-immune cell types alike [12].  
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Siglec-F is a member of the Siglec family and was first identified as an eosinophil 
marker in mouse [7]. Siglec-F recognizes the NeuAcα2-3Gal[6S]β1-4GlcNAc motif printed 
on the synthetic glycan microarray [13], and it is proposed that binding of Siglec-F to a 
related glycan expressed on mouse lung potentiates eosinophil death in the lung during 
allergic asthma [14]. Accordingly, Siglec-F deficient mice exhibit increased numbers of lung-
infiltrating eosinophils during an asthmatic state [15]. While these studies have established a 
suppressive function for Siglec-F on eosinophils, the role of Siglec-F in other cell-types, such 
as alveolar macrophages [16] and activated T cells [15], remains unclear.  
 
We generated a monoclonal antibody recognizing Siglec-F to investigate its cell type 
expression and biological roles in mouse tissues and cells. Although attention to expression 
of Siglec-F has focused on immune cells in blood, spleen, and lymph nodes, we noted a 
single report of the presence of Siglec-F mRNA in mouse M cells [17]. As described here, 
we found that Siglec-F protein is indeed expressed on the luminal surface of small intestinal 
M cells. Furthermore, the Siglec-F antibody bound to M cells upon injection into the small 
intestine, demonstrate the potential of M cell targeting via Siglec-F. 
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2. Materials and methods 
2.1. Animals 
C57BL/6J WT and Siglec-F KO (Mutant Mouse Resource Research Center, University of 
California Davis, USA) mice and Lewis rats were maintained in the specific pathogen free 
animal facility at The Scripps Research Institute (San Diego, USA). C57BL/6J and Balb/c 
mice were maintained in the specific pathogen free animal facility at the University of East 
Anglia (Norwich, UK). Animal use in this study was in the accordance with the guidelines of 
the Institutional Animal Care and Use Committee of The Scripps Research Institute and the 
UK home office. 
 
2.2. Anti-Siglec-F monoclonal antibody generation 
The anti-Siglec-F monoclonal antibody (rat IgG2b, clone 9C7) was generated as described 
previously [18]. Briefly, Lewis rats were immunized with Siglec-F-expressing CHO cells 
emulsified in complete Freund’s adjuvant (Difco Laboratories). Following two boosts of the 
cells emulsified in incomplete Freund’s adjuvant (Difco Laboratories), the immunized rats 
were sacrificed and the common iliac lymph nodes were harvested to generate hybridomas. 
The established hybridomas were screened for reactivity to Siglec-F-CHO cells and Siglec-
F-expressing HEK293 cells by flow cytometry. The selected anti-Siglec-F expressing 
hybridoma was grown for 7-10 days, and the antibody was purified from the culture 
supernatant and labelled with Alexa Fluor-647 (Life Technologies). 
 
2.3. Flow cytometry 
PPs were harvested from mouse small intestine and vortexed in PBS vigorously. The 
supernatant was removed, and this washing step was repeated three times. Washed PPs 
were incubated with 10 ml of PBS containing 5 mM EDTA and 1 mM DTT for 30 min at 37ºC, 
in order to remove cells localized in the epithelia. The solution was passed through a 40 µm-
cell strainer and centrifuged. The harvested cells were incubated with FcR-blocking antibody 
(Biolegend, clone 93) and stained with anti-M cell antibody NKM16-2-4 (MP Biomedicals) for 
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30 min at 4°C, followed by Biotin-labelled anti-rat  IgG2c (Southern Biotech). The cells were 
further stained with a cocktail of Alexa647-labelled anti-Siglec-F antibody, Alexa700-labelled 
anti-mouse CD45 (Biolegend, clone: 30-F11), PE-labelled anti-mouse CCR3 (Biolegend, 
J073E5), PE-Cy7-labelled CD11b (Biolegend, M1/70), FITC-labelled UEA-I (Vector lab), and 
Pacific blue-labelled streptavidin (Life Technologies). The stained cells were washed and 
resuspended in 0.3 µg/ml propidium iodide for dead cell exclusion prior to analysis on 
Fortessa or LSR II cell analyzers (BD Biosciences). Data were analyzed by FlowJo 
(Treestar). 
 
2.4. Microscopy 
Terminal ileum PPs were harvested from C57BL/6J mice, washed in 1x PBS, snap frozen in 
OCT (Bright CRYO-M-BED), and cryosectioned at 8-µm thickness. Sections were fixed for 5 
min with -20ºC methanol, washed once with PBS containing 0.05% Tween-20 (PBS-T), and 
washed twice with PBS. All subsequent incubations were performed at RT. Sections were 
treated with 3% H2O2 in PBS for 30 min. After washing once with PBS-T and twice with PBS, 
slides were blocked with PBS containing 6% BSA and 10% normal mouse serum (Southern 
Biotech) for 30 min. Anti-mouse Siglec-F or isotype control (10 µg/ml) and UEA-I-FITC (20 
µg/ml) were applied for 60 min. After washing, as described above, sections were incubated 
for 30 min with mouse anti-rat IgG2b-HRP (Southern Biotech, 2 µg/ml). Sections were 
washed once with PBS-T, washed four times with 1x PBS, and treated for 5 min with Cy-3 
Plus TSA reagent (Perkin Elmer) according to the manufacturer’s instructions. After washing 
once with PBS-T and four times with PBS, sections were incubated with anti-mouse M cell 
antibody NKM16-2-4 (25 µg/ml). After 60 min the slides were washed and treated with 
biotinylated anti-rat IgG2c (10 µg/ml) for 30 min, washed, and stained for 20 min with 
Alexa647 conjugated streptavidin and counterstained with DAPI (5 µg/ml). Sections were 
imaged with the Zeiss Axio Imager M2, and data were analyzed with ZEN 2 (blue edition).  
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2.5. Intestinal loop assay 
Balb/c mice were anesthetized with a continuous flow of isoflurane. The small intestine was 
exposed via laparotomy, and an intestinal loop containing PPs was made using threads (Fig. 
3). Five micrograms of Alexa647-labeled anti-Siglec-F or isotype control antibody (Rat IgG2b, 
Biolegend) was injected into the loop. The mice were sacrificed 15 min after inoculation, and 
PPs were harvested. The Alexa647 signal associated with M cells was analyzed by flow 
cytometry. 
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3. Results and Discussion 
3.1. Generation of a Siglec-F monoclonal antibody 
In order to study Siglec-F expression profile on mouse tissues, we generated a monoclonal 
antibody to Siglec-F. Briefly, Lewis rats were immunized with Siglec-F expressing CHO cells. 
Hybridomas were established by fusing myeloma cell line with the lymphocytes from 
common iliac lymph nodes of the immunized animals. Hybridoma screening was performed 
based on the antibody reactivity to Siglec-F expressing CHO cells and HEK293 cells by flow 
cytometry. The established clone 9C7 produced a rat IgG2b monoclonal antibody, which 
binds to Siglec-F expressed on HEK293 cells (Fig. 1). 
 
3.2. Expression of Siglec-F on PP M cells 
A report showing Siglec-F mRNA expression in mouse M cells [17] motivated us to 
investigate Siglec-F protein expression on mouse M cells using our Siglec-F monoclonal 
antibody (clone 9C7). PP M cells were identified as CD45-UEA-I+NKM16-2-4+ by flow 
cytometric analysis as reported previously [17]. We found that PP M cells did indeed express 
Siglec-F when compared to an isotype control at levels comparable to eosinophils 
(CD45+CD11b+CCR3+) (Fig. 2A and B). Staining of M cells with the antibody clone 9C7 was 
specific for Siglec-F, since M cells isolated from Siglec-F KO mice stained at levels 
equivalent to the isotype control (Fig. 2B). In the immunohistochemical analysis, we found 
that Siglec-F staining was co-localized with the UEA-I and NKM16-2-4 signals in frozen 
sections of PP (Fig. 2C). Of note, Siglec-F expression was observed on the intestinal luminal 
surface of M cells (Fig 2C, arrows). Together these data demonstrate that Siglec-F is 
expressed on the luminal surface of mouse PP M cells. 
 
3.3. In vivo M cell targeting by anti-Siglec-F antibody 
To test whether M cells are targeted by Siglec-F antibody, Alexa647-labelled anti-
Siglec-F or the isotype control antibody were injected intraluminally into a small intestine 
loop created by ligatures (Fig. 3A). PPs were harvested, and cells were analyzed by flow 
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cytometry. We found that the Siglec-F antibody bound to M cells, but not to eosinophils - 
presumably because the eosinophils are not exposed to the intestinal lumen - demonstrating 
the potential of M cell targeting through Siglec-F via the intestinal lumen (Fig. 3B). 
 
Our findings suggest a novel role for Siglec-F in M cells, opening up several key 
questions to be addressed; a) Since Siglec-F is well documented to have endocytic activity 
[19], to what extent might it contribute to the antigen transport by M cells? In this regard, 
Siglec-F has been shown to internalize the sialylated microbe Neisseria meningitides into the 
cell [19], suggesting a potential role for Siglec-F on M cells as a receptor for sialylated 
microorganisms in the gut. b) Is Siglec-F involved in survival of M cells? To determine 
whether the function of Siglec-F on M cells is analogous to its function in eosinophils, it is 
important to test whether antibodies and glycan ligands toward Siglec-F also regulate the 
survival of M cells.  
 
In humans, Siglec-8 is characterized as a functional paralogue of Siglec-F, exhibiting 
the same expression pattern and glycan-binding specificity [7]. Interestingly, Siglec-5 has 
been reported to be expressed in human M cells [11]. Therefore, it would of interest to 
assess whether Siglec-5 and Siglec-F are functional paralogues on M cells. 
 
In summary, we have identified Siglec-F expression on mouse M cells. The receptor can be 
targeted by antibody in vivo, which suggests that we could exploit Siglec-F to deliver antigen 
to M cells. The discovery of Siglec receptors on both mouse (Siglec-F) and human (Siglec-5) 
on M cells suggests a potentially conserved biological function for Siglecs in the gut. 
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Figure legends 
Figure 1 A new anti-Siglec-F monoclonal antibody binds to Siglec-F expressing 
HEK293 cells. HEK 293 cells expressing Siglec-F or mock transfectant were stained with 
Alexa 647-labelled Siglec-F (Black) or isotype control (Grey) antibody. The stained cells 
were analyzed by flow cytometry. Data are representative of two independent experiments 
with similar results. 
 
Figure 2 Siglec-F expression on PP M cells 
(A) Cells isolated from the epithelial fraction of PPs were stained with anti-Siglec-F (Black) or 
isotype control (Grey) antibody together with the other cell surface markers. Stained cells 
were analyzed by flow cytometry. Dead cells were excluded from the analysis by propidium 
iodide staining. (B) PPs from WT and Siglec-F KO mice were analyzed for their reactivity to 
the Siglec-F antibody clone 9C7 as in (A). Mean fluorescent intensity (MFI) in Siglec-F 
staining is shown for both M cells and eosinophils. ***, p < 0.001 and N.S., not statistically 
significant in the Student’s t-test (n = 4). (C) Frozen sections of PPs were stained with anti-
Siglec-F antibody, UEA-I, and NKM16-2-4. Blue signals show nuclear staining with DAPI. 
The bottom panels are enlarged images of the luminal side of PPs (white box). White arrows 
show the overlapping of the three signals. White bars in the top and bottom panel are 50 µm 
and 10 µm, respectively. Data are representative of at least two independent experiments 
with similar results. 
 
Figure 3 In vivo M cell targeting by anti-Siglec-F antibody 
Alexa647-labelled anti-Siglec-F (Black) or isotype control (Grey) antibody was injected into 
the small intestine of Balb/c mice. After 15 min of inoculation, PPs were harvested, and the 
cells were stained as in Fig. 2. Data are representative of two independent experiments with 
similar results. 
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Highlights 
• A new monoclonal antibody recognizing Siglec-F has been established. 
• Siglec-F is expressed on mouse Peyer’s patch microfold (M) cells. 
• Siglec-F antibody binds to PP M cells in vivo. 
